For the roughly half of all spinal cord injury patients who endure chronic neuropathic pain, the search for relief has long meant choosing between imperfect medications and the well-documented dangers of opioids. A team of researchers at UC San Diego has now demonstrated, in animal trials, that a single injection of gene therapy can silence pain-signaling neurons at the precise site of injury for months at a time — without the side effects that have made existing treatments so difficult to live with. The path to human trials remains long and uncertain, but the study offers something the field
UPI News
· May 16, 2022
· health
· 2 min read
Medium
Sourcing: Characterized
Gene therapy shows promise for spinal cord injury pain in mouse studies
Approximately 50% of spinal cord injury patients experience chronic neuropathic pain, tingling, numbness, or muscle weakness that significantly impacts quality of life.
◉
Health & Medicine
8525 related articles
FDA Approves Pancreatic Cancer Drug That May Extend Patient Survival
CBS News · 100% match
Eli Lilly Seeks FDA Approval for Tirzepatide as Weight Loss Drug
ScienceAlert · 99% match
Eli Lilly's Oral GLP-1 Pill Shows Promise for Diabetes and Weight Loss
TODAY · 99% match
Eli Lilly Seeks FDA Approval for Tirzepatide as Weight-Loss Treatment
Interesting Engineering · 99% match
Retatrutide: Eli Lilly's Triple-Action Weight-Loss Drug Poised to Resh…
The Economic Times · 99% match
Related Coverage
BBC News · Aug 27
Facebook horse seller ordered to pay damages after selling unfit animals to buyers
Five women report being mis-sold unsafe or injured horses by a Facebook seller, with one buyer's daughter suffering a se…
Al Jazeera · Aug 27 Pakistan hospital fire kills 14 infants; families demand accountabilityFourteen babies died in a fire at Islamabad's Institute of Medical Sciences. Grieving families accuse hospital staff and…
Peter Attia MD · Aug 27 GLP-1 drugs show promise beyond metabolism, but questions remain about whyGLP-1 medications, originally developed for type 2 diabetes, now show potential benefits across metabolic and non-metabo…
Korea JoongAng Daily · Aug 27 Korean researchers identify Erbb4 protein as potential Alzheimer's breakthroughKorean researchers identified the Erbb4 protein as a key driver of Alzheimer's progression, showing it triggers synapse …
Bias & Framing
No detailed analysis data available for this lens. Try re-running lenses from the admin panel.
Geopolitical Impact
🌎
This is a medical research article about gene therapy for spinal cord injury pain, not a geopolitical matter.
Escalation Risk
N/A
Confidence
HIGH
Economic Lens
📈
Gene therapy shows promise for treating spinal cord injury pain in mice, potentially reducing opioid dependence and creating new pharmaceutical/biotech market opportunities.
Market Signal
bullish
Confidence
MED
Biotechnology/Gene Therapy
Pharmaceutical Manufacturing
Healthcare Services
Medical Devices
Opioid Industry
Patients with spinal cord injuries and neuropathic pain could access non-opioid pain management alternatives, reducing addiction risks and medication side effects. However, high treatment costs and limited accessibility in early stages may restrict benefits to wealthy populations initially.
FDA may accelerate gene therapy approval pathways; healthcare regulators could shift reimbursement policies away from opioids toward gene therapies; potential reduction in opioid prescriptions could impact pharmaceutical revenue but improve public health outcomes; insurance coverage debates likely to emerge regarding cost-benefit of one-time gene therapy versus ongoing medication.